Holger Reithinger PhD
Senior Advisor
Harnessing one of the most essential pathways in the innate immune system to generate effective therapies.
Rigontec is a leading company in the immune-oncology field developing compounds interacting with RIH-I receptor. The company was acquired August 2017 by MSD for up to EUR 463 million.
Industry
Biotech
Status
Past
Location
Germany
Forbion team